Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells

BACKGROUND: Identification and validation of a targeted therapy for triple-negative breast cancer (TNBC), that is, breast cancers negative for oestrogen receptors, progesterone receptors and HER2 amplification, is currently one of the most urgent problems in breast cancer treatment. EGFR is one of t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Caiazza, F, McGowan, P M, Mullooly, M, Murray, A, Synnott, N, O'Donovan, N, Flanagan, L, Tape, C J, Murphy, G, Crown, J, Duffy, M J
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2015
Assuntos:
Translational Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4580380/
https://ncbi.nlm.nih.gov/pubmed/26010411
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2015.163
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados